Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop ...

Novo Nordisk’s Wegovy weight loss pill hit U.S. pharmacies this week. Here’s how it works, who qualifies, how to take it, ...

Researchers found weight returns far faster after stopping GLP-1 drugs than after diet or exercise programmes On average, ...

Alveus, founded in early 2024 by Philadelphia- and Belgium-based New Rhein Healthcare Investors, is trying to develop obesity treatments that are more tolerable and have greater durability.

Stopping weight loss medication led to weight regain and reversed improvements in cardiometabolic markers in under 2 years, ...

A major study finds that weight loss drugs work while used, but weight and health benefits often return after stopping ...

The research, published in the British Medical Journal on Thursday, adds to a growing body of evidence that suggests ...

When people stop taking the new generation of weight-loss drugs, they pile back on the kilos four times faster than they ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual ...

GLP-1 medicines have been utilised for the treatment of diabetes; however, they are now emerging as important topics for the treatment of obesity ...